$APUS

Apimeds Pharmaceuticals US, Inc. (APUS) has filed a Form NT 10-Q with the SEC, indicating that it will be submitting its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026, late. The company stated it requires additional time to finalize its financial statements and expects to file the report within the five-calendar-day extension period permitted under Rule 12b-25. No significant change in the results of operations from the corresponding period for the last fiscal year is anticipated.

Apimeds Pharmaceuticals US (APUS) received a notice of noncompliance from NYSE American on April 17, 2026, for failing to file its 2025 Form 10-K. The company has a six-month cure period, remains listed with a ".LF" designation, and its trading halt from April 2, 2026, is still in effect.

Apimeds Pharmaceuticals US, Inc. (APUS) has filed a Form 12b-25 notification with the SEC, indicating that it will be late in filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The company requires additional time to complete financial statements and for its independent auditor to finalize the review and audit. APUS anticipates filing the 10-K within the fifteen-day grace period allowed by Rule 12b-25.

Hopewell, New Jersey, May 12, 2025 ( GLOBE NEWSWIRE ) -- Apimeds Pharmaceuticals US, Inc. ( NYSE American: APUS ) ( "Apimeds" or the "Company" ) , a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally administered bee venom-based toxin which ...